Gene · 3003
NIH grants2,103
NIH grants whose papers are about the gene, through NIH's grant-paper links.
1,361 to 1,380 of 2,103
Download this page as JSON| Grant | Title | GZMK papers | Newest fiscal year |
|---|---|---|---|
| R01MD010443 | Genes, air pollution, and asthma severity in minority children | 1 | 2020 |
| R01NS097728 | Dynamic Neuroimmune Profiling in Patients with Acute Intracerebral Hemorrhage | 1 | 2020 |
| R03DK117253 | Defining the Generation and Cargo of Extracellular Vesicles During the Evolution of Type 1 Diabetes | 1 | 2020 |
| R21AG064159 | Neuroprotective function of microglial TREM2 in TDP43-related neurodegeneration | 1 | 2020 |
| R21AI141178 | Discovery of therapeutics against Cryptococcosis by Repurposing Pharmaceutical Libraries | 1 | 2020 |
| R21AI141367 | Plasmodium phospholipase A2s as potential novel drug targets | 1 | 2020 |
| R21AI142264 | Single cell analysis of transplant rejection | 1 | 2020 |
| R21AI143301 | Mechanisms of varicella virus dissemination | 1 | 2020 |
| R21AI146969 | Mechanistic understanding of SH3 domain-containing protein function in alphavirus replication | 1 | 2020 |
| R21CA223093 | Combatting Bladder Cancer by Inducing Epithelial Turnover | 1 | 2020 |
| R21CA231277 | (PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockade | 1 | 2020 |
| R21CA231280 | (PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapy | 1 | 2020 |
| R21CA238971 | The prognostic landscape of gender- and ethnicity-specific immune influences on cancer outcomes | 1 | 2020 |
| R21CA252364 | Exploring enzyme-instructed self-assembly (EISA) for targeting osteoblastic metastasis of prostate cancer | 1 | 2020 |
| R21HD099367 | Mechanisms of metabolic dysfunction in the offspring of maternal obesity: role of inflammation | 1 | 2020 |
| R35CA197743 | Dissecting Pediatric Brain Tumor Microenvironment to Improve Treatment | 1 | 2020 |
| R37NS083580 | Ras Proteins in Nerve Tumorigensis | 1 | 2020 |
| R42CA228875 | Targeting glioblastoma stem-like cells with custom-designed viral vectors | 1 | 2020 |
| R50CA211481 | MULTIMODAL PRECLINICAL CANCER IMAGING AND THERAPY RESEARCH SPECIALIST | 1 | 2020 |
| R50CA211482 | Immunogenomic analytical approaches for research and clinical applications | 1 | 2020 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3003/grants?page=69